Plasmid DNA Manufacturing Market Growth Accelerated by Rising Demand for Gene Therapies

Plasmid DNA Manufacturing Market


Plasmid DNA is circular, double-stranded DNA molecule capable of autonomous replication distinct from chromosomal DNA. It is commonly used as a genetic vector to deliver therapeutic genes into cells and tissues for gene therapy and genetic vaccination. Plasmid DNA can be produced efficiently and rapidly at a large scale using microbial fermentation systems. With the rising use of plasmid DNA as a backbone for delivering gene sequences in gene and cell therapies, the demand for plasmid DNA manufacturing services is increasing significantly.

The global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The increasing demand for gene therapies to treat various chronic diseases like cancer, cardiovascular disease, infectious diseases, and rare genetic disorders has been the major factor driving the growth of the plasmid DNA manufacturing market. Plasmid DNA is a critical raw material for developing gene therapy and genetic vaccines. As more gene therapy candidates enter clinical trials and fewer receive regulatory approvals for commercialization, the demand for high quality plasmid DNA for research and development activities is also growing substantially. Advanced technologies like process analytical technology (PAT) for real-time release testing and continuous manufacturing are being adopted by plasmid DNA manufacturers to satisfy the increasing demand and ensure quality, safety and efficacy of plasmid DNA products.

Segment Analysis
The global plasmid DNA manufacturing market is dominated by GMP grade plasmid DNA sub segment. It accounts for over 65% of the total market share as most of the gene and cell therapies, DNA vaccines under clinical trials and research require GMP grade plasmid DNA for the purpose of consistency and safety. These plasmid DNA’s are required to meet stringent quality requirements for therapeutic applications and hence this sub segment is witnessing high demand.

Key Takeaways
The global plasmid DNA manufacturing market is expected to witness high growth over the forecast period of 2023 to 2030. Global Plasmid DNA Manufacturing Market Size is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023-2030.

North America currently dominates the global plasmid DNA manufacturing market owing to presence of major players, growing biopharmaceutical industry and rising investment in R&D for cell and gene therapies by both public and private players in the region. The regional market is expected to continue its domination during the forecast period.

Key players operating in the plasmid DNA manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc. Cobra Biologics is a global contract development and manufacturing organization offering plasmid DNA production services. Charles River Laboratories acquired Cobra in 2018 to strengthen its position in gene therapy market. VGXI Inc. offers high quality GMP grade plasmid DNA services and solutions for vaccine and gene therapy development

The global plasmid DNA manufacturing market size for 2024 is US$ 901.2 Bn forecast period is from 2023 to 2030 with CAGR of 4.8%. The market is expected to grow owing to rising demand for GMP grade plasmid DNA from cell and gene therapy developers and DNA vaccine manufacturers.


Comments

Popular posts from this blog

Security Robot Market is Estimated To Witness High Growth Owing To Increasing Demand for Enhanced Surveillance

The Ever-Evolving Landscape of the Scottish Whisky Market during the Forecast Period 2019-2027

Monochloroacetic Acid (MCAA) Market Is Estimated To Witness High Growth Owing To Increasing Demand for Surfactants and Herbicides